Form 4: RA Capital Management Reports Director's Acquisition of 16,000 PepGen Stock Options

RA Capital Management, a significant shareholder and director of PepGen Inc., reported the acquisition of 16,000 stock options for PepGen common stock at an exercise price of $1.51, granted to director Joshua Resnick.

Summary

• RA Capital Management, L.P., along with related entities and individuals (RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev M. Shah), filed a Form 4 regarding PepGen Inc. (PEPG).
• The filing reports the acquisition of 16,000 stock options to buy PepGen common stock.
• These options were granted on June 4, 2025, with an exercise price of $1.51 per share and an expiration date of June 3, 2035.
• The options were granted to Joshua Resnick, a Partner of RA Capital Management, L.P., who serves on PepGen's board of directors.
• The options will vest in full upon the earlier of June 4, 2026, or the date of PepGen's next Annual Stockholder Meeting, provided Dr. Resnick continues to serve as a director.
• Dr. Resnick holds these options for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund II, L.P., and a separately managed account, and is obligated to turn over any net proceeds from exercise to the Adviser to offset advisory fees.
• The reporting persons disclaim beneficial ownership of the options and underlying common stock, except to the extent of their respective pecuniary interest therein.

Sentiment

Score: 7

Explanation: The grant of stock options to a director and significant shareholder is generally a positive signal, indicating alignment of interests and confidence in future performance, despite the disclaimer of direct personal beneficial ownership by the reporting individuals.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, incentivizing long-term value creation.
• The exercise price of $1.51 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• The reporting persons disclaim direct beneficial ownership of the options, indicating that the direct financial benefit flows to the funds managed by RA Capital rather than personally to the named individuals, which is standard for such arrangements but means the individual director's direct personal stake is limited to their indirect interest in the funds.

Risks

• Vesting of the options is contingent on Dr. Resnick's continued service as a director, meaning the benefit is tied to his ongoing role.
• The value of the options is dependent on PepGen Inc.'s stock price exceeding the $1.51 exercise price.

Future Outlook

The vesting schedule for the granted stock options indicates a future milestone for the director's equity compensation, tied to continued service and the company's next Annual Stockholder Meeting.

Management Comments

• "RA Capital Management, L.P. (the 'Adviser') is the investment manager for RA Capital Healthcare Fund, L.P. (the 'Fund'), RA Capital Nexus Fund II, L.P. (the 'Nexus Fund II'), and a separately managed account (the 'Account')."
• "Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."
• "Under Dr. Resnick's arrangement with the Adviser, Dr. Resnick holds the option for the benefit of the Fund, the Nexus Fund II and the Account. Dr. Resnick is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser."
• "Joshua Resnick, a Partner of the Adviser, serves on the Issuer's board of directors."

Industry Context

This filing is a standard disclosure for insider transactions, common across all industries, particularly for publicly traded companies where directors and significant shareholders receive equity-based compensation or make open market transactions. In the biotechnology sector, where PepGen Inc. likely operates, such grants are a typical component of executive and director compensation packages, aligning their incentives with long-term company performance.

Related Party Transactions

• The stock option grant to Joshua Resnick, a director of PepGen Inc. and a Partner of RA Capital Management, L.P. (a 10% owner and investment manager for other reporting entities), constitutes a related party transaction. Dr. Resnick holds the option for the benefit of RA Capital's funds, with proceeds offsetting advisory fees.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a significant shareholder (RA Capital) and a director with other shareholders, as the value of the options depends on the company's stock price appreciation.
• Management/Directors: Dr. Resnick's compensation is now further tied to the company's long-term performance.

Next Steps

• Monitoring the vesting of the 16,000 stock options, which is contingent on Dr. Resnick's continued service as a director until June 4, 2026, or the next Annual Stockholder Meeting.
• Observing any future exercises of these options by the reporting entities.

Key Dates

Recommendation

Keywords

PepGen Inc., PEPG, RA Capital Management, Stock Option, Insider Transaction, Form 4, Beneficial Ownership, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals